Search hospitals > Alaska > Anchorage
Providence Alaska Medical Center
Claim this profileAnchorage, Alaska 99508
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Recurrence
Conducts research for Tumors
Conducts research for Lung Cancer
332 reported clinical trials
9 medical researchers
Summary
Providence Alaska Medical Center is a medical facility located in Anchorage, Alaska. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Tumors, Lung Cancer and other specialties. Providence Alaska Medical Center is involved with conducting 332 clinical trials across 545 conditions. There are 9 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Brenda J. Wittman, and Nitya Alluri.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Alison K. ConlinProvidence Portland Medical Center4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
99 reported clinical trials
175 drugs studied
Charles W. DrescherProvidence Portland Medical Center1 year of reported clinical research
Expert in Cancer
Studies Tumors
44 reported clinical trials
85 drugs studied
Brenda J. WittmanProvidence Alaska Medical Center6 years of reported clinical research
Expert in Tumors
Expert in Lymphoma
33 reported clinical trials
75 drugs studied
Nitya AlluriProvidence Portland Medical Center1 year of reported clinical research
Expert in Cancer
Studies Recurrence
28 reported clinical trials
79 drugs studied
Clinical Trials running at Providence Alaska Medical Center
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Gastric Cancer
Brain Tumor
Pancreatic Cancer
Multiple Myeloma
Acute Lymphoblastic Leukemia
Tumors
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Providence Alaska Medical Center?
Providence Alaska Medical Center is a medical facility located in Anchorage, Alaska. This center is recognized for care of Cancer, Breast Cancer, Recurrence, Tumors, Lung Cancer and other specialties. Providence Alaska Medical Center is involved with conducting 332 clinical trials across 545 conditions. There are 9 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Brenda J. Wittman, and Nitya Alluri.
Where is Providence Alaska Medical Center located?
**Providence Alaska Medical Center**
- **Address:** 3200 Providence Drive, Anchorage, AK 99508
- **Directions:** Accessible via Seward Highway; exit onto Providence Drive, hospital will be on the left.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance-related inquiries at Providence Alaska Medical Center, please contact the Financial Assistance Team at 855-229-6466. For billing customer service regarding clinics and physicians, dial 907-212-6522, and for hospital billing inquiries, call 907-212-6500.
What insurance does Providence Alaska Medical Center accept?
Providence Alaska Medical Center accepts a wide range of insurance plans, including but not limited to Premera, Aetna Medicare Advantage PPO, Anthem Blue Cross HMO/PPO, Blue Shield of CA HMO/PPO, Choice/Humana PPO, Cigna PPO, and United Healthcare PPO. For the most accurate and current information on accepted insurance plans, please contact the hospital directly.
What awards or recognition has Providence Alaska Medical Center received?
Providence Alaska Medical Center, located in Anchorage, Alaska, is honored as a 2023-24 Best Regional Hospital by U.S. News & World Report, excelling in seven types of care. The hospital proudly holds its second Magnet designation, highlighting its commitment to nursing excellence and the positive impact on the community.